drugset / Trial / NCT01200784

Nicotinamide in Hemodialysis Patients With Hyperphosphatemia

NCT01200784

Phase 2 Completed 252 enrolled Medice Arzneimittel Pütter GmbH & Co KG
RandomizedParallel-groupDouble-blindTreatment

Summary

Study hypothesis: Nicotinamide inhibits gastrointestinal phosphate absorption and serum phosphate levels of dialysis patients in a dose dependent manner.

Timeline

Start
2010-08
Primary completion
2011-06
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotinamide Other / unclassified 250 mg
Subject Nicotinamide Other / unclassified 500 mg
Subject Nicotinamide Other / unclassified 750 mg
Subject Nicotinamide Other / unclassified 1000 mg